Eva Grasa
Dados Biográficos
| ID | 6778089 |
|---|---|
| NOME | Eva Grasa |
| PRENOMES | Eva |
| SOBRENOME | Grasa |
| ASSINATURA | GRASA E |
| AFILIAÇÕES | Centro de Investigación Biomédica en Red de Salud Mental |
| ORCID | 0000-0003-1100-7489 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 6 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 6 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2016 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2024 |
| ÍNDICE H | 0 |
The influence of metacognition, social cognition, self-esteem, and quality of life on personal stigma in first-episode psychosis
Project e-Motiph
BackgroundThe implementations of Information and Communication Technologies (ICT) models focused on the patient’s perspective are needed to identify potential consequences and gaps of clinical practice and to improve quality of care. This is particularly important for patients with complex conditions, such as patients with schizophrenia and persistent symptoms, who consume more healthcare resources and require an integrated care. Patient Journey …
A Method to Compare the Delivery of Psychiatric Care for People with Treatment-Resistant Schizophrenia
Although the availability of services was different in each region, most of the services provided were sufficiently similar to allow the implementation of the same ICT solution in the three places
Results of the m-Resist feasibility study. A Mobile therapeutic attention for treatment-resistant schizophrenia
The International Journal of Integrated Care (IJIC) is an online, open-access, peer-reviewed scientific journal that publishes original articles in the field of integrated care on a continuous basis.IJIC has an Impact Factor of 5.120 (2020 JCR, received in June 2021)
M-Resist, a modular intervention programme addressed to patients with treatment-resistant schizoprenia
In European Union, between 0.2 and 2.6% of the population suffer from psychotic disorders (Wittchen et al., 2011). The largest group is patients with schizophrenia, and around 40% can be considered resistant to pharmacological treatment (Essock et al., 1996; Kennedy et al., 2014). Standard intervention in patients with treatment-resistant schizophrenia (TRS) is difficult due to the persistence of positive symptoms, extensive periods of hospitaliz…
An innovative and integrative m-Health solution for treatment resistant schizophrenia patients
In the European Union, it is estimated that around 5 million people (0.2-2.6%) suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant (Juarez-Reyes et al., 1995; Essock et al., 1996). The standard intervention in patients with resistant schizophrenia is complex, mainly for the presence of persistent positive symptomatology, extensive periods of hospital care and greater risk of multi-m…
Sem obras proeminentes nesta página.
An innovative and integrative m-Health solution for treatment resistant schizophrenia patients
In the European Union, it is estimated that around 5 million people (0.2-2.6%) suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant (Juarez-Reyes et al., 1995; Essock et al., 1996). The standard intervention in patients with resistant schizophrenia is complex, mainly for the presence of persistent positive symptomatology, extensive periods of hospital care and greater risk of multi-m…
M-Resist, a modular intervention programme addressed to patients with treatment-resistant schizoprenia
In European Union, between 0.2 and 2.6% of the population suffer from psychotic disorders (Wittchen et al., 2011). The largest group is patients with schizophrenia, and around 40% can be considered resistant to pharmacological treatment (Essock et al., 1996; Kennedy et al., 2014). Standard intervention in patients with treatment-resistant schizophrenia (TRS) is difficult due to the persistence of positive symptoms, extensive periods of hospitaliz…
Results of the m-Resist feasibility study. A Mobile therapeutic attention for treatment-resistant schizophrenia
The International Journal of Integrated Care (IJIC) is an online, open-access, peer-reviewed scientific journal that publishes original articles in the field of integrated care on a continuous basis.IJIC has an Impact Factor of 5.120 (2020 JCR, received in June 2021)
A Method to Compare the Delivery of Psychiatric Care for People with Treatment-Resistant Schizophrenia
Although the availability of services was different in each region, most of the services provided were sufficiently similar to allow the implementation of the same ICT solution in the three places
Project e-Motiph
BackgroundThe implementations of Information and Communication Technologies (ICT) models focused on the patient’s perspective are needed to identify potential consequences and gaps of clinical practice and to improve quality of care. This is particularly important for patients with complex conditions, such as patients with schizophrenia and persistent symptoms, who consume more healthcare resources and require an integrated care. Patient Journey …
The influence of metacognition, social cognition, self-esteem, and quality of life on personal stigma in first-episode psychosis
Psychiatry (6 obras) · Medicine (5 obras) · Schizophrenia (object-oriented programming (5 obras) · Digital Mental Health Interventions (4 obras) · Psychology (3 obras) · Health care (2 obras) · Intervention (counseling (2 obras) · Mental Health and Psychiatry (2 obras) · Mental Health Treatment and Access (2 obras) · Mobile Health and mHealth Applications (2 obras)